Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to HAIC. An C, Fu Y, Li W, Zuo M, et al. Cancer 2023 Apr 7. doi: 10.1002/cncr.34764.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

An C, Fu Y, Li W, Zuo M, et al. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to HAIC. Cancer 2023 Apr 7. doi: 10.1002/cncr.34764.
PMID: 37029486